ArticleCerebrum : the Dana forum on brain science2012
Cognitive impairment in multiple sclerosis: a forgotten disability remembered.
Article in Cerebrum : the Dana forum on brain science, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Cholinesterase inhibitors for rarer dementias associated with neurological conditions.The Cochrane database of systematic reviews · 2015Pooled it
- The Relationship between Cognitive Dysfunction and Postural Stability in Multiple Sclerosis.Medicina (Kaunas, Lithuania) · 2021Trial
- Computer-assisted cognitive rehabilitation in persons with multiple sclerosis: Results of a multi-site randomized controlled trial with six month follow-up.Disability and health journal · 2018Trial
- Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing-remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study).Journal of neurology · 2017Trial
- Motor, Cognitive, Psychological, and Neural Predictors of Concern About Falling in Persons With Multiple Sclerosis.Neurorehabilitation and neural repair · 2026Article
- Advanced MRI Techniques: Diagnosis and Follow-Up of Multiple Sclerosis.Diagnostics (Basel, Switzerland) · 2024Review
- Neuroprotective effects of gemfibrozil in neurological disorders: Focus on inflammation and molecular mechanisms.CNS neuroscience & therapeutics · 2024Review
- Cognitive, behavioral and psychiatric symptoms in patients with spinal cord injury: a scoping review.Frontiers in psychiatry · 2024Article
- Scale development to evaluate differences between concern about falling and fear of falling: the concern and fear of falling evaluation.Frontiers in psychology · 2024Article
- Rehabilitation therapy versus drug-only therapy in patients with multiple sclerosis.Turkish journal of medical sciences · 2024Observational
- Effectiveness of exercise interventions in animal models of multiple sclerosis.Frontiers in medicine · 2023Review
- Oligodendroglia are emerging players in several forms of learning and memory.Communications biology · 2022Review
- MSProDiscuss™ Clinical Decision Support Tool for Identifying Multiple Sclerosis Progression.Journal of clinical medicine · 2022Review
- Effects of Palmitoylethanolamide on Neurodegenerative Diseases: A Review from Rodents to Humans.Biomolecules · 2022Review
- Contributing Factors to the Quality of Life in Multiple Sclerosis.Medical archives (Sarajevo, Bosnia and Herzegovina) · 2020Article
- Cognitive Disorders in Patients with Multiple Sclerosis.Materia socio-medica · 2020Article
- CD8+ T Cell-Mediated Mechanisms Contribute to the Progression of Neurocognitive Impairment in Both Multiple Sclerosis and Alzheimer's Disease?Frontiers in immunology · 2020Review
- SeXX Matters in Multiple Sclerosis.Frontiers in neurology · 2020Review
- Speech Discrimination Tasks: A Sensitive Sensory and Cognitive Measure in Early and Mild Multiple Sclerosis.Frontiers in neuroscience · 2020Article
- Effects of enhanced environment and induced depression on cuprizone mouse model of demyelination.Experimental and therapeutic medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Physicians first noted the presence of cognitive impairment in patients with multiple sclerosis (MS) more than 160 years ago, yet it took clinicians until 2001 to codify a standard test to measure cognitive function. We now know that cognitive impairment occurs in up to 65 percent of people with MS and usually lessens their ability to remember previously learned information. So far, trials of drugs formulated to treat cognitive impairment have failed, but the authors remain optimistic that new approaches to diagnosis and drug development could lead to effective therapies in the future.
Identifiers
23447800PMC3574761W2210712264What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.